AQST News and Press, Aquestive Therapeutics Inc. From 08/05/20

For  Q2 , Aquestive Therapeutics ( AQST +6.2% ) revenues of $21.7M vs. $11.1M; indicating increased licensing fees and royalty revenue ($12M for KYNMOBI approval). More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,...

Aquestive Therapeutics, Inc. (AQST) Q2 2020 Results Earnings Conference Call August 5, 2020, 08:00 AM ET Company Participants Stephanie Carrington - Westwicke, Investor Relations Keith Kendall - President and Chief Executive Officer John Maxwell - Senior Vice President and Chief ...

Aquestive Therapeutics (NASDAQ: AQST ) : Q2 GAAP EPS of -$0.07 beats by $0.36 . More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Generated 59% year-over-year revenue growth for Sympazan ® (clobazam)    FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokinetics (PK) clinical trials  Continues to advance Libervant™ (diazepam...

WARREN, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wi...

WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...

Aquestive Therapeutics (NASDAQ: AQST ) has submitted an IND application to the FDA for pharmacokinetic (PK) clinical trials of AQST-108, an oral sublingual film formulation delivering systemic epinephrine in development for the treatment of anaphylaxis (serious allergic reaction). M...

Expects to initiate its planned pharmacokinetic (PK) clinical trials before year end 2020 This program will be reviewed under the 505(b)(2) regulatory approval pathway AQST-108 may address an unmet need in patients requiring rescue medication for anaphylaxis WARREN, N.J., June 29, 20...

WARREN, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wi...

WARREN, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that due to the p...